晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/...晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/程序性死亡-配体1(programmed cell death ligand 1,PD-L1)抑制剂被美国食品药品监督管理局(Food and Drug Administration,FDA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准用于治疗晚期尿路上皮癌[4-6]。另外,成纤维生长因子受体(fibroblast growth factor receptor,FGFR)抑制剂与抗体偶联(antibody-drug conjugate,ADC)药物的研究取得突破,并先后被批准用于临床[7-11]。展开更多
BACKGROUND Primary signet ring cell carcinoma of the urethra in women is an exceedingly rare malignancy.It was first reported in postmenopausal women in 1987,and only five patients have been reported to date.CASE SUMM...BACKGROUND Primary signet ring cell carcinoma of the urethra in women is an exceedingly rare malignancy.It was first reported in postmenopausal women in 1987,and only five patients have been reported to date.CASE SUMMARY A 61-year-old woman presented with irregular vaginal bleeding,and subsequent evaluation identified a tumor located in the distal urethra.Upon diagnosis of primary urethral carcinoma,she underwent a distal urethrectomy.Histopathological analysis demonstrated that the tumor consisted of a combination of intestinal adenocarcinoma and signet ring cell carcinoma.At the 12-month postoperative follow-up,there was no evidence of disease recurrence.CONCLUSION This case report highlights the exceptional rarity of female urethral signet ring cell carcinoma,emphasizing the importance of early clinical detection and the necessity for precise and conservative surgical intervention.展开更多
淋巴瘤是发生人体免疫系统比较常见的恶性肿瘤,多发生于淋巴结内,分为霍奇金淋巴瘤和非霍奇金淋巴瘤,非霍奇金淋巴瘤发病率较高,非霍奇金淋巴瘤分很多亚型,其中成人最常见的亚型是弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBC...淋巴瘤是发生人体免疫系统比较常见的恶性肿瘤,多发生于淋巴结内,分为霍奇金淋巴瘤和非霍奇金淋巴瘤,非霍奇金淋巴瘤发病率较高,非霍奇金淋巴瘤分很多亚型,其中成人最常见的亚型是弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL),此现象同样适用于结外,结外发生DLBCL约占30%~40%,多见于胃肠道,据文献报道,原发于输尿管,发病率很低,并且预后差,5年生存率为59%~82%[1]。我院收治1例,现报告如下。展开更多
文摘晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/程序性死亡-配体1(programmed cell death ligand 1,PD-L1)抑制剂被美国食品药品监督管理局(Food and Drug Administration,FDA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准用于治疗晚期尿路上皮癌[4-6]。另外,成纤维生长因子受体(fibroblast growth factor receptor,FGFR)抑制剂与抗体偶联(antibody-drug conjugate,ADC)药物的研究取得突破,并先后被批准用于临床[7-11]。
基金Supported by the Science and Technology Bureau Foundation of Jinhua,No.2021-4-300 and No.2020-3-062The Zhejiang Provincial Medical and Health Science and Technology Plan,No.2025KY1752。
文摘BACKGROUND Primary signet ring cell carcinoma of the urethra in women is an exceedingly rare malignancy.It was first reported in postmenopausal women in 1987,and only five patients have been reported to date.CASE SUMMARY A 61-year-old woman presented with irregular vaginal bleeding,and subsequent evaluation identified a tumor located in the distal urethra.Upon diagnosis of primary urethral carcinoma,she underwent a distal urethrectomy.Histopathological analysis demonstrated that the tumor consisted of a combination of intestinal adenocarcinoma and signet ring cell carcinoma.At the 12-month postoperative follow-up,there was no evidence of disease recurrence.CONCLUSION This case report highlights the exceptional rarity of female urethral signet ring cell carcinoma,emphasizing the importance of early clinical detection and the necessity for precise and conservative surgical intervention.
文摘淋巴瘤是发生人体免疫系统比较常见的恶性肿瘤,多发生于淋巴结内,分为霍奇金淋巴瘤和非霍奇金淋巴瘤,非霍奇金淋巴瘤发病率较高,非霍奇金淋巴瘤分很多亚型,其中成人最常见的亚型是弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL),此现象同样适用于结外,结外发生DLBCL约占30%~40%,多见于胃肠道,据文献报道,原发于输尿管,发病率很低,并且预后差,5年生存率为59%~82%[1]。我院收治1例,现报告如下。
